John Koconis

John has had a highly accomplished career as both a strategic and operational leader in the pharmaceutical sector with over 25 years of experience leading successful teams in global markets and launching multiple market-leading products. John brings a unique perspective through his experience in broad, specialty and rare/orphan dermatology development and commercialization.

As President & CEO of LEO Pharma (US), he opened a successful U.S. affiliate for the European based LEO A/S, establishing a market-leading dermatology company with a primary focus on psoriasis and AK. After 15 years with LEO, John moved to Sanofi/Genzyme where, as the Global Lead for Dermatology and Respiratory Disease, he led the Global launch of dupilumab, the first biologic for moderate to severe atopic dermatitis. After Sanofi Genzyme, John joined Castle Creek Pharmaceuticals as the EVP and Chief Commercial Officer to prepare for the commercialization of the company’s epidermolysis bullosa asset and transition the company towards a commercial stage. This experience across the different areas of dermatology has allowed John to build a broad and diverse network within global dermatology and with KOLs in multiple indications. John holds an MBA from Loyola University Graduate School of Business and a BS in Biology from Loyola University-Chicago.